Navigation Links
Market Research Shows Spherix's Naturlose(R) Readily Accepted by Diabetes Patients

Meets MD's Treatment Need

BETHESDA, Md., May 12 /PRNewswire/ -- Naturlose, a natural sugar approved as a food ingredient in the U.S. and abroad, has been found to reduce the spikes of serum glucose that follow consumption of food (1). In a Phase 3 human clinical trial, Spherix (Nasdaq: SPEX) is currently studying the efficacy and safety of Naturlose for the treatment of diabetes. While the Phase 3 trial is ongoing, Spherix has engaged market research companies to seek feedback as to the likelihood of Naturlose market acceptance assuming successful completion of the Phase 3 trials and ultimate FDA approval.

Focus group testing with diabetes patients and physicians who treat diabetes has identified a clear role for Naturlose in the management of diabetes. A series of focus group meetings were held in two U.S. cities. The testing included demographically diverse groups of both general practitioners and endocrinologists, as well as patients ranging from the age of 30 to 70.

Patients, many of whom suffer side effects from current oral diabetes medications, valued the safety of a natural product already approved for use in food. Patients expressed a preference for the soft chewable formulation, with the fast-dissolving oral and powdered forms ranking second and third, respectively. The convenience of meal-time dosing was also mentioned by patients. Patients expressed a clear need for more information about diabetes. Many feared the long-term consequences of poor long-term control of blood glucose and were eager to have practical advice on improving their health.

Physicians, who treat diabetes with multiple drugs, each acting at a different biochemical point to control blood sugar, were intrigued by Naturlose's novel mechanism of action. For physicians, drug choice was a complex algorithm involving level of glucose control, tolerance to side effects, cost, and patient compliance. The consensus of the physicians was that with three of four of the most widely prescribed drugs to treat type 2 diabetes, patient toleration of side effects limited their ability to achieve the glycemic control that they seek for their patients. Physicians expressed significant frustration with the ability of current medications to control patients' blood sugar to guideline-based goals, and saw value in being able to add a safe new therapeutic approach to their arsenal.

Both patients and physicians expressed interest in the safety and efficacy data currently being developed for Naturlose in the Phase 3 trial. Because Naturlose is approved as a food ingredient and the food-grade sugar is available, both patients and physicians had the opportunity to taste Naturlose during the focus group meetings. The sweet flavor had great appeal. After tasting Naturlose one general practitioner remarked, "We are all going to start taking it."

Data from the national prescription audit of the diabetes category for 2007 revealed 167,019,000 total prescriptions, with 58,015,000 new prescriptions. The diabetes category remained very active in 2007. Price level and positioning on insurer and managed care formularies are important issues that manufacturers continuously address. Regardless of product launch date, the share of new prescriptions remains around 30%. More recent brand product launches with the largest marketing budgets show a higher share of new prescriptions. However, generics with recent launches are also showing year-to-year prescription growth. As a result, significant opportunities exist for Spherix over the next several years.

1. Yongming Lu, Gilbert Levin, Thomas Donner. Tagatose, a New

Anti-Diabetic and Obesity-Control Drug. Diabetes, Obesity and

Metabolism. 10, 2008, 109-134.

Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission, including the filing on Form 8-K made on October 10, 2007.

Spherix's mission is to create value and increase shareholder wealth through innovations that benefit our clients and the human condition. Spherix offers innovations in biotechnology, and provides technical and regulatory consulting services to biotechnology and pharmaceutical companies.

Spherix's Internet address is

SOURCE Spherix
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AHIP Statement on CMS Proposed Medicare Marketing Regulations
2. Conseco Reaches Settlement of Multistate Market Conduct Examination
3. Self-Medication One of Many Factors Driving OTC Drug Market Past $80 Billion by 2012
4. Fougera First-to-Market With Calcipotriene Topical Solution 0.005% (Rx) (Scalp Solution)
5. Cadient Group Continues Winning Streak; Receives Multiple Honors at 2008 Pharmaceutical Advertising and Marketing Excellence Awards
6. Triple-S Management Corporation Reports First Quarter 2008 Results; Cites Growth Resulting From Strong Market Position
7. Customer Communications Group Selected by The Childrens Hospital for Direct Marketing Expertise
8. Strategies for Winning Clinical Investigators in a Competitive Marketplace
9. Marketing Executives Finding Value in Best Practice Database
10. David Pizzo Appointed Blue Cross and Blue Shield of Florida Market President - West Florida
11. Osteotech Engages BioHorizons as Exclusive Distributor to International Dental Market
Post Your Comments:
(Date:11/28/2015)... CA (PRWEB) , ... November 28, 2015 , ... Pixel ... fully customizable media panels to choose from, the possibilities are endless. Users have full ... more. With the ProPanel: Pulse masking effects, users are sure to get heads to ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... new study carried out by the University of Toronto and the University of British ... number of hospitalizations for head injuries. The article explains that part of the reason ...
(Date:11/27/2015)... ... 2015 , ... A team of Swiss doctors has released a report on ... just posted the findings on the website. Click here to read the details ... mesothelioma patients who were treated with chemotherapy followed by EPP surgery. Among the 106 ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion ... off of their purchase of lice treatment product. In addition, customers will receive a ... company spokesperson. “Finding lice is a sure way to ruin the holidays, so we ...
(Date:11/27/2015)... LOS ANGELES, CA (PRWEB) , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only ... age of 30 (see Table 1-1 ). More than 3.7 billion people under ... simplex virus type 1 (HSV-1), according to WHO's first global estimates of HSV-1 infection ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Competitive Intelligence, ... --> ) has ... Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... Research and Markets ( ) has announced the ... Type (Dressings, Therapy Devices, Active Wound Care), Application (Surgical ... Geography - Global Forecast to 2020" report to ... --> The purpose of this report is to ... advanced wound care market. It involves deep dive analysis ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... of the "Self Administration of High Viscosity ... ) has announced the addition of ... report to their offering. --> ... the addition of the "Self Administration of ...
Breaking Medicine Technology: